Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 28 Nov 2023 07:00 CET |
ARGENX SE | argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia | 20103010 Biotechnology | Other subject |
| 16 Nov 2023 13:40 CET |
ARGENX SE | argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis | 20103010 Biotechnology | Other subject |
| 01 Nov 2023 07:00 CET |
ARGENX SE | argenx to Present at Upcoming Investor Conferences | 20103010 Biotechnology | Other subject |
| 01 Nov 2023 07:00 CET |
ARGENX SE | argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions | 20103010 Biotechnology | Other subject |
| 31 Oct 2023 07:00 CET |
ARGENX SE | argenx Reports Third Quarter 2023 Financial Results and Provides Business Update | 20103010 Biotechnology | Other subject |